SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies-Reference-Cited by-同舟云学术

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

Published:2022-02-18 Issue:6582 Volume:375 Page:782-787
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Reincke S. Momsen¹²³^ORCID,Yuan Meng⁴^ORCID,Kornau Hans-Christian²⁵^ORCID,Corman Victor M.⁶⁷⁸^ORCID,van Hoof Scott¹²³^ORCID,Sánchez-Sendin Elisa¹²³,Ramberger Melanie²³^ORCID,Yu Wenli⁴^ORCID,Hua Yuanzi⁴,Tien Henry⁴^ORCID,Schmidt Marie Luisa⁶⁷,Schwarz Tatjana⁶⁷^ORCID,Jeworowski Lara Maria⁶⁷^ORCID,Brandl Sarah E.¹²³,Rasmussen Helle Foverskov¹²³^ORCID,Homeyer Marie A.¹²³^ORCID,Stöffler Laura¹²³^ORCID,Barner Martin³^ORCID,Kunkel Désirée⁹^ORCID,Huo Shufan¹^ORCID,Horler Johannes¹²³,von Wardenburg Niels¹²³^ORCID,Kroidl Inge¹⁰¹¹,Eser Tabea M.¹⁰¹¹^ORCID,Wieser Andreas¹⁰¹¹,Geldmacher Christof¹⁰¹¹,Hoelscher Michael¹⁰¹¹^ORCID,Gänzer Hannes¹²^ORCID,Weiss Günter¹³^ORCID,Schmitz Dietmar²⁵,Drosten Christian⁶⁷^ORCID,Prüss Harald¹²³^ORCID,Wilson Ian A.⁴¹⁴^ORCID,Kreye Jakob¹²³¹⁵^ORCID

Affiliation:

1. Department of Neurology and Experimental Neurology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

2. German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.

3. Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.

4. Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

5. Neuroscience Research Center (NWFZ), Cluster NeuroCure, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

6. Institute of Virology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

7. German Centre for Infection Research (DZIF), Berlin, Germany.

8. Labor Berlin–Charité Vivantes GmbH, Berlin.

9. Flow and Mass Cytometry Core Facility, Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin, Germany.

10. Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany.

11. German Center for Infection Research (DZIF), partner site Munich, Germany.

12. Department of Internal Medicine, BKH Schwaz, Schwaz, Austria.

13. Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

14. The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

15. Department of Pediatric Neurology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant of concern (VOC) resists neutralization by major classes of antibodies from COVID-19 patients and vaccinated individuals. In this study, serum of Beta-infected patients revealed reduced cross-neutralization of wild-type virus. From these patients, we isolated Beta-specific and cross-reactive receptor-binding domain (RBD) antibodies. The Beta-specificity results from recruitment of VOC-specific clonotypes and accommodation of mutations present in Beta and Omicron into a major antibody class that is normally sensitive to these mutations. The Beta-elicited cross-reactive antibodies share genetic and structural features with wild type–elicited antibodies, including a public VH1-58 clonotype that targets the RBD ridge. These findings advance our understanding of the antibody response to SARS-CoV-2 shaped by antigenic drift, with implications for design of next-generation vaccines and therapeutics.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference45 articles.

1. Antibody evasion by the P.1 strain of SARS-CoV-2

2. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

3. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

4. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

5. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells;Nature Biotechnology;2024-08-14

2. Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern;Vaccine;2024-08

3. Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants;Proceedings of the National Academy of Sciences;2024-07-30

4. Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS‐CoV‐2 neutralization;Immunity, Inflammation and Disease;2024-07

5. Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1;Cell Reports;2024-06